Evidence map›Paper›PMID 40369357›Full record

ArticleInternational urology and nephrology2025

A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis.

Shaolong Zhang, Chuanjian Chen, Chunhao Mo, Ning Fan, Zhongyun Ning, Zhiping Wang, Hui Ding

Abstract readClinical Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shaolong ZhangDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Chuanjian ChenDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Chunhao MoDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Ning FanDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhongyun NingDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhiping WangDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Hui DingDepartment of Urology, Gansu Province Clinical Research Center for urinary system disease, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. dingh08@126.com.

Funding

Basic research of science and technology innovation application - surface project CY2021-MS-B03Department of Science and Technology of Gansu Province 21JR1RA119
6 · The paper itself

Abstract

objectivesThis study aimed to evaluate the efficacy and safety of RC48-ADC combined with PD-1 inhibitors in bladder preservation therapy for muscle-invasive bladder cancer (MIBC), and to explore the differences in treatment outcomes between primary and recurrent cases, as well as patients at different clinical stages.

methodsA retrospective analysis was conducted on 32 patients with clinically non-metastatic MIBC who received ≥ 3 cycles of RC48-ADC combined with PD-1 inhibitor therapy. Clinical efficacy was assessed through integrated imaging and histopathological evaluations.

resultsAmong the 32 patients, the 1-year progression-free survival (PFS) rate was 84.4%, the objective response rate (ORR) was 68.8%, and the 1-year bladder preservation rate was 68.8%. The primary group was superior to the recurrent group in PFS (94.7% vs. 69.2%), ORR (78.9% vs. 53.8%), and 1-year bladder preservation rate (78.9% vs. 53.8%). Similarly, T2-stage patients exhibited better clinical responses than T3-stage patients in PFS (85.0% vs. 75.0%), ORR (80.0% vs. 54.5%), and 1-year bladder preservation rate (80.0% vs. 54.5%). Treatment-related adverse events (AEs) were predominantly grade I-II, with no severe immune-related complications reported.

conclusionsThe combination of RC48-ADC and PD-1 inhibitors significantly improves bladder preservation rates in MIBC patients with a favorable safety profile, particularly in primary and T2-stage cases. This regimen provides a personalized therapeutic strategy for patients unsuitable for conventional treatments.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsOrgan Sparing TreatmentsUrinary BladderUrinary Bladder NeoplasmsAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleFollow-Up StudiesHumansImmunoconjugatesInjections, IntravenousMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, Humanizeddisitamab vedotinImmune Checkpoint InhibitorsImmunoconjugatesOligopeptidesPDCD1 protein, humanProgrammed Cell Death 1 ReceptortislelizumabtoripalimabBladder preservation therapyImmune combination therapyMuscle-invasive bladder cancerPD-1 inhibitorRC48-ADC

Identifiers

PMID40369357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.